To view this page ensure that Adobe Flash Player version 11.1.0 or greater is installed.

Measuring the Quality of Life of Patients with Cancer HRQoL. This trial compared WBRT with observation following either surgery or radiosurgery of a limited number of brain metastases in patients with stable solid tumours. Patients who received WBRT reported lower scores for global health status, physical/cognitive functioning and fatigue, and showed that WBRT following surgery or radiosurgery of a limited number of brain metastases may negatively impact HRQoL; observation with close monitoring by MRI instead of WBRT did not harm HRQoL. 4 Patient-reported Outcomes versus Proxy Assessment – HRQoL Research in a Novel Area Assessing HRQoL in patients with brain tumours is challenging. As one would imagine, a commonly reported symptom of patients with gliomas is cognitive deficits, and these also hamper adequate reporting of HRQoL by the patient. Exclusion of patients with cognitive deficits from analysis obviously leads to underreporting of such problems as concentration, memory, reading/writing, … in the evaluation of HRQoL during experimental treatment. In EORTC trial 26091, a currently open trial assessing the significance of bevacizumab in recurrent grade II and grade III gliomas, two EORTC HRQoL instruments are being used to assess patient QoL through their caregivers or relatives (proxies). The assessments reported by the patients will then be compared with those reported by their proxies. It would be interesting to find out if the proxies can represent patient views and to what extend the two are in agreement. If proxies have a different perspective, the next question would be which reports the more accurate information. Meta-analysis of HRQoL data has been proven clinically informative and, despite the challenges of funding HRQoL research and the complexities of pooling data together, EORTC supports the development the new methods of electronic assessment of PROs and storage in the central EORTC database. Such efforts increase the volume of HRQoL dataset and stimulate numerous efficiency comparisons that can inform clinicians, policy makers, health care payers, etc. A further development that EORTC is pursuing is the use of HRQoL data collection via computer systems instead of the classic paper questionnaires. Such electronic systems would have several advantages, both for the patient (automatic language selection, adaptive display format …) as well as the researchers (automatic data transfer, real-time updates on compliance …). In order to have a machine-independent system, EORTC is developing an online version that will run in all common web-browsers and does not require any local software installation. Once validated, this can be extended to handheld devices and to introduce the questionnaires that can be adapted according to the clinical status of the patient or tailored to his/ her previous answers. About the EORTC The EORTC brings together European cancer clinical research experts from all disciplines for trans-national collaboration. Both multinational and multidisciplinary, the EORTC Network comprises more than 2,000 collaborators from all disciplines involved in cancer treatment and research in more than 300 hospitals in over 30 countries. Future Opportunities Through translational and clinical research, the EORTC offers an The patient’s perspective has consistently been considered important in palliative and curative EORTC trials, and recent findings have altered clinical practice and provide data needed to support major recommendations and future improvements. Clinicians, regulatory bodies and industry representatives acknowledge the value of the patient perspective, and the EORTC will continue to include HRQoL endpoints where appropriate. integrated approach to drug development, drug-evaluation programmes and medical practices. EORTC Headquarters, a unique pan-European independent clinical research infrastructure, is based in Brussels, Belgium, from where its various activities are coordinated and run (visit n 1. Quinten C, Coens C, Mauer M, et al., Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials, Lancet Oncol, 2009;10(9):865–71. 2. Eggermont AM, Suciu S, Santinami M, et al., Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial, Lancet, 2008;372(9633):117–26. 3. Bottomley A, Coens C, Suciu S, et al., Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group, J Clin Oncol, 2009;27(18):2916–23. 4. Soffietti R, Kocher M, Abacioglu UM, et al., A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results, J Clin Oncol, 2013;31(1):65–72. E U ROPE A N O N CO LO G Y & H A EMATO LO G Y 11